Jefferies Upgrades Marvell (MRVL) to Buy

Jefferies upgraded Marvell (NASDAQ: MRVL) from Hold to Buy with a price target of $27.00 (from $18.50).

Analyst Mark Lipacis believes the combination with CAVM generates a product portfolio with synergies and believes the deal creates better scale. The analyst believes there is a high probability the deal gets approval from regulatory agencies.

For an analyst ratings summary and ratings history on Marvell click here. For more ratings news on Marvell click here.

Shares of Marvell closed at $21.59 yesterday.

You May Also Be Interested In

• Marvell (MRVL) PT Raised to $345 at B.Riley, bullish on new CEO
• Glenmark Pharmaceuticals Ltd. (GNP:IN) PT Raised to INR2,750 at Investec
• McGraw Hill (MH) PT Lowered to $14 at UBS on Softer 2027 Outlook